Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use.

Drug design, development and therapy - 1 Jan 2015

Li Chuan-Jiang, Li Liang

Abstract excerpt

Tacrolimus is a product of fermentation of Streptomyces, and belongs to the family of calcineurin inhibitors. It is a widely used immunosuppressive drug for preventing solid-organ transplant rejection. Compared to cyclosporine, tacrolimus has greater immunosuppressive potency and a lower incidence of side effects. It has been accepted as first-line treatment after liver and kidney transplantation. Tacrolimus has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotransformation
Share to Calcineurin Inhibitors
Share to Graft Rejection

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Graft Survival

Share to Liver Transplantation

Share to Medication Adherence

Share to Patient Satisfaction

Share to Tacrolimus

Source

Open in PubMed Open full text

Identifiers

PMID: 25609922
DOI: 10.2147/DDDT.S41349
PMCID: PMC4298305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use.PMID 25609922Read ↗

Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients.Semantic proximity Read ↗

Dosing strategy of tacrolimus when co-administered with Wuzhi tablet in renal transplant recipients.Semantic proximity Read ↗

Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients.Semantic proximity Read ↗

Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.Semantic proximity Read ↗

Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.Semantic proximity Read ↗

[Personalized medicine in transplantation therapy].Semantic proximity Read ↗

Effect of Wuzhi preparations on tacrolimus in CYP3A5 expressers during the early period after transplantation: A real-life experience from heart transplant recipients.Semantic proximity Read ↗

Beneficial effects of traditional Chinese medicine Wuzhi Capsule on tacrolimus dose requirements in liver transplant patients with different donor-recipient CYP3A5 genotypesSemantic proximity Read ↗

Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics.Semantic proximity Read ↗

Multicenter Prospective Trial Evaluating the Utility of CYP3A5 Genotype in Determining Optimal Initial Dosage of Tacrolimus in Chinese Renal Transplant RecipientsSemantic proximity Read ↗

Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.Semantic proximity Read ↗

Effects of WuZhi preparations on tacrolimus in pediatric and adult patients carrying the CYP3A5*1 allele of heart transplant during the early period after transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.